Today, Artivion announced that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) for the use of the AMDS Hybrid Prosthesis (“AMDS”) in acute DeBakey Type I dissections in the presence of malperfusion. The AMDS is the world’s first aortic arch remodeling device for use in treating acute DeBakey Type I aortic dissections. Learn more: https://lnkd.in/e-jgv9UH
Artivion LATAM
Biotechnology Research
Kennesaw, Georgia 826 followers
Advancing Aortic Technologies With Purpose™
About us
Artivion is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. Our purpose is to develop simple, elegant solutions that address cardiac and vascular surgeons’ most difficult challenges in treating patients with diseases of the aorta and deliver breakthrough technologies of unsurpassed quality that have far-reaching impact. Our decades of expertise in treating aortic diseases—coupled with our recent acquisitions and partnerships—have empowered us to offer cardiac and vascular surgeons a suite of aortic-centric solutions such as cryopreserved cardiac and vascular allografts, surgical sealants, prosthetic heart valves, and aortic stents and stent-grafts. Artivion has over 1,250 employees worldwide with sales representation in over 100 countries. The Company has manufacturing facilities located in Atlanta, Georgia, Austin, Texas, and Hechingen, Germany. Additionally, it has sales and distribution offices in various countries throughout Europe, Asia, and South America.
- Website
-
http://www.artivion.com
External link for Artivion LATAM
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Kennesaw, Georgia
- Founded
- 1982
Updates
-
Another milestone in Lima, Peru! Today, we successfully treated a patient with a thoracoabdominal aneurysm using our pre-cannulated multibranch Enside stent graft. The procedure achieved exceptional results, with four inner branches cannulated efficiently, minimizing fluoroscopy time and contrast use. A step forward in innovation and patient care. Congratulations to the heart team of Dr. Akira Tsuha Alvarado, Dra. Jenny Sandoval Huarcaya and our proctor support by Dr. Juan Martin. Thanks to our local partners Percy Garcia Alfredo Rodriguez Colina CARDIOMED SAC
-
-
Exciting advancements in thoraco-abdominal aneurysm therapy! 🚀 We’re thrilled to announce the successful clinical launch of our TAAA pre-cannulated E-nside device in Mexico 🇲🇽 , led by the talented Dr. Gioele Simonte from Perugia, Italy. This breakthrough device is capturing global attention, transforming approaches, and reshaping the future of patient care. Together, we’re redefining possibilities in endovascular therapy. Thanks to DDM GROUP - Medical Device Design and Development our partners and exclusive representatives for organize this event. Artivion, Inc. #InnovationInAction #EndovascularSurgery #EndovascularRevolution #TAAA #EnsideDevice #ClinicalAdvancement”
-
-
-
-
-
+3
-
-
Join us tomorrow, November 7th, for our teleconference call and live webcast at 4:30 p.m. ET to discuss the Q3 financial results, followed by a question and answer session hosted by Pat Mackin, Chairman, President, and Chief Executive Officer of Artivion. Learn more today: https://bit.ly/3NX1zgC
-
Neste Dia do Médico, celebramos o compromisso, a dedicação e o cuidado de todos os profissionais que, com ciência e empatia, dedicam-se a salvar e melhorar vidas. Que o esforço diário de vocês seja sempre reconhecido e valorizado, e que a paixão por cuidar continue guiando cada gesto. Parabéns a todos os médicos, que são verdadeiros heróis da saúde!
-
-
Today, data from our AMDS DARTS and PERSEVERE trials and E-vita Open Neo study were presented in Late-Breaking Science presentations at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Lisbon, Portugal. The presentation regarding the AMDS DARTS trial highlighted 5-year aortic remodeling data that demonstrate positive, durable patient outcomes following AMDS implantation. The presentation on the 30-day AMDS PERSEVERE trial data showed cerebral malperfusion resolution for 90% of affected subjects at 30 days post-AMDS implantation. Additionally, the presentation on the 1-year data from the NEOS study showed E-vita Open Neo is safe and effective for the treatment of acute and chronic aortic arch pathologies with a lower combined major adverse event rate compared to the market leading alternative. Read the full press release today! https://bit.ly/401nSsS
-
-
We are excited to announce that we will attend the 38th EACTS Annual Meeting in Lisbon. We anticipate a full schedule with engaging podium sessions, a lively lunch symposium focusing on our aortic arch solutions, and updates on late-breaking clinical trials like DARTS, PERSEVERE, and NEOS. Discover more about Artivion's Clinical Power at EACTS 2024. https://bit.ly/3ZZUWkG #EACTS2024 #cardiothoracicsurgery #CTSurgery #AorticSurgery
-
Today is Aortic Dissection Awareness Day. It's also a day for us to come together, share knowledge, and reaffirm our commitment to partnering with surgeons worldwide in treating patients suffering from aortic dissections. We proudly announce that this year, Artivion is donating to two charitable associations devoted to raising awareness about aortic dissection: The John Ritter Foundation and The Aortic Charitable Donation Trust. The funds donated to both foundations will help provide education and resources to patients and families impacted by aortic dissection. Check out this year's John Ritter Foundations Aortic Champions, who are helping spread the word about Aortic Dissections. https://bit.ly/3MS4BSG
-